NCT02559791View on ClinicalTrials.gov

Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

August 31, 2017

Conditions
Severe Persistent AsthmaEosinophilic Bronchitis
Interventions
BIOLOGICAL

Reslizumab

Reslizumab 3ml/kg once monthly for 4 months

DRUG

Placebo

Matching placebo once monthly for 2 months

Trial Locations (1)

L8N 4A6

Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

collaborator

St. Joseph's Healthcare Hamilton

OTHER

lead

McMaster University

OTHER

NCT02559791 - Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma | Biotech Hunter | Biotech Hunter